May 29, 2018
In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment.
With budgets being tight and time scarce, outsourcing has become more common. Additionally, risk, perception and regulation have limited the adoption of biologics, biosimilars and biobetters, as small molecules and synthetic drugs have been the traditional therapeutic standard. Fortunately, innovative biological therapeutic tools and technologies are now proven to be viable, highly effective, low risk and safe.
This article was written by Dr Michael Mouradian
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: